David M Stack, Director and CEO & Chairman, reported a sale of 13,115 shares in Pacira Biosciences (PCRX) for $562,377 on Jul 08, 2019. Following the Form...
The 2019 and 2020 full year forecasted earnings estimates for Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 43.42) have been scaled up. The...
Pacira Pharmaceuticals' (PCRX) said its Exparel anesthetic, when given to dental patients getting wisdom teeth removed, reduced the use of post-surgery...
Pacira Pharmaceuticals (PCRX) said pre-market Tuesday that the European Medicines Agency has approved the company's Marketing Authorization Application for...
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 07/10/2019 4 |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| President | Max Reinhardt |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
| Price Open | $40.35 |
| Previous Close | $40.46 |
| 52 Week Range | $35.07 - 55.00 |
| Market Capitalization | $1.6 B |
| Shares Outstanding | 41.3 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 08/01/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 238.00 |
| Earnings per Share | $0.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 2.10% |
| Return on Equity | 2.40% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
